AstraZeneca has opened its new production and packaging plant in Kaluga, Russia.
Worth around $224m, the facility represents the largest foreign investment made for developing a new pharmaceutical facility in the country.
Commercial production for the plant has been scheduled to start next year.
Expected to be completely operational in 2017, the production and packaging facility will be used by the company for final-stage manufacturing, packaging and quality control of its products.
AstraZeneca CEO Pascal Soriot said: "This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long-term commitment to Russia."
The plant will have a capacity to produce nearly 40 million packs and 850 million tablets of around 30 medicines every year for the pharmaceutical and biologics company.
The capacity accounts for more than 60% of AstraZeneca’s medicines marketed in Russia for treatment of diseases across its therapy areas.
This plant is expected to support the AstraZeneca’s global expansion plans, which intend to cater to the rising market demands for its portfolio of medicines.
The firm has recently invested in biologics manufacturing operations in Sweden, acquired a new site in Boulder, Colorado, US, and expanded its capabilities at Frederick in Maryland, US.
Image: Capacity of the new facility accounts for more than 60% of AstraZeneca’s medicines marketed in Russia. Photo: courtesy of AstraZeneca.